文献速递药物不良反应与药物警戒

达比加群逆转剂依达赛珠单抗在I期研究中的免疫原性评价

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
PubMed 文献 · Br J Clin Pharmacol · 2017-04-06

本分析汇总三项I期随机双盲研究,在健康白人、老年肾功能不全者及健康日本人群中检测依达赛珠单抗抗药抗体(ADA)。283例中33例(11.7%)存在预存ADA,用药后224例中19例(8.5%)出现治疗相关ADA,滴度均极低,未见免疫反应相关不良事件,预存ADA未影响依达赛珠单抗的PK/PD。

要点

  • 预存ADA滴度极低,估计等效于5 g剂量后循环依达赛珠单抗的<0.3%
  • 治疗相关ADA多为短暂性,特异性主要针对依达赛珠单抗C端
  • 预存ADA未影响依达赛珠单抗剂量归一化峰浓度与暴露量

核心结论

  • 预存与治疗相关ADA水平相对于所评价的依达赛珠单抗剂量极低,预存ADA似不影响依达赛珠单抗的PK/PD,未见免疫反应相关不良事件。

研究设计与样本

  • 汇总三项I期随机双盲依达赛珠单抗研究,对象为健康白人、老年肾功能不全者及健康日本人;采用经验证的电化学发光法检测并滴定血浆ADA,并比较有无预存ADA者的PK/PD。

主要发现

  • ADA滴度低,估计等效于5 g剂量后循环依达赛珠单抗的<0.3%;多数治疗相关ADA主要针对依达赛珠单抗C端。
  • 预存ADA未影响剂量归一化依达赛珠单抗最大血浆水平与暴露量,数据有限但未见影响达比加群诱导抗凝的逆转。

局限性

  • ADA对达比加群抗凝逆转影响的数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Idarucizumab, a humanized monoclonal anti-dabigatran antibody fragment, is effective in emergency reversal of dabigatran anticoagulation. Pre-existing and treatment-emergent anti-idarucizumab antibodies (antidrug antibodies; ADA) may affect the safety and efficacy of idarucizumab. This analysis characterized the pre-existing and treatment-emergent ADA and assessed their impact on the pharmacokinetics and pharmacodynamics (PK/PD) of idarucizumab. METHODS: Data were pooled from three Phase I, randomized, double-blind idarucizumab studies in healthy Caucasian subjects; elderly, renally impaired subjects; and healthy Japanese subjects. In plasma sampled before and after idarucizumab dosing, ADA were detected and titrated using a validated electrochemiluminescence method. ADA epitope specificities were examined using idarucizumab and two structurally related molecules. Idarucizumab PK/PD data were compared for subjects with and without pre-existing ADA. RESULTS: Pre-existing ADA were found in 33 out of 283 individuals (11.7%), seven of whom had intermittent ADA. Titres of pre-existing and treatment-emergent ADA were low, estimated equivalent to <0.3% of circulating idarucizumab after a 5 g dose. Pre-existing ADA had no impact on dose-normalized idarucizumab maximum plasma levels and exposure and, although data were limited, no impact on the reversal of dabigatran-induced anticoagulation by idarucizumab. Treatment-emergent ADA were detected in 20 individuals (19 out of 224 treated [8.5%]; 1 out of 59 received placebo [1.7%]) and were transient in ten. The majority had specificity primarily toward the C-terminus of idarucizumab. There were no adverse events indicative of immunogenic reactions. CONCLUSION: Pre-existing and treatment-emergent ADA were present at extremely low levels relative to the idarucizumab dosage under evaluation. The PK/PD of idarucizumab appeared to be unaffected by the presence of pre-existing ADA.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Norris S, Ramael S, Ikushima I, et al. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. Br J Clin Pharmacol. 2017. PMID: 28230262. doi:10.1111/bcp.13269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。